This paper is available online at http://dmd.aspetjournals.org
The cytochromes P450 (P450) are a superfamily of hemoproteins that are involved in oxidative, peroxidative, and reductive metabolic biotransformation of a wide variety of endogenous compounds, such as steroids, prostaglandins, and fatty acids, and exogenous compounds, such as drugs and carcinogens (Ortiz de Montellano, 1995; Nelson et al., 1996) . Individual P450s exhibit unique substrate specificity and regio-and stereoselectivity profiles that reflect different tertiary structures. The CYP2B subfamily contains some of the first P450s to be cloned and purified and has served as a model system for mammalian P450 structure-function analysis through the use of allelic variants, site-directed mutagenesis, and computer-aided molecular modeling (Lewis et al., 1999; ). The CYP2B1 substrate recognition site residues 103, 114, 115, 206, 209, 290, 294, 297, 298, 302, 362, 363, 367, 477, 478, and 480 have been demonstrated to be very important for substrate metabolism . Human CYP2B6 metabolizes about 3% of drugs in clinical use, and structure-function analyses have only recently begun as new clinically relevant substrates have been identified (Rendic and Di Carlo, 1997) and heterologous expression has been accomplished (Hanna et al., 2000) . More work is necessary to understand the structure and specificity of CYP2B6 and its role in metabolism.
Recently efforts have intensified to use the quantitative structureactivity relationship (QSAR) for understanding P450 active sites (Ekins et al., 2001) . Such approaches are based on the idea of combining chemical knowledge about small compounds with experimental data obtained from in vitro systems. A considerable number of current QSAR models have been generated for P450s, especially for CYP2B6, 2C9, 2D6, and 3A4 (Koymans et al., 1992; Strobl et al., 1993; Jones et al., 1996; Rao et al., 2000; Ekins et al., 1999a Ekins et al., ,b,c,d, 2000 . The QSAR approaches used include comparative molecularfield analysis, Catalyst, and molecular surface-weighted holistic invariant molecular analysis. Comparative molecular-field analysis is dependent on the alignment of small compounds, whereas Catalyst is alignment independent. In some cases, the pharmacophores were combined with homology models of P450s and provide a more powerful tool to investigate the active-site features and substrate interactions (de Groot et al., 1999a,b; Afzelius et al., 2001) . A novel and selective CYP2D6 substrate, which is suitable for high-throughput screening, has already been successfully designed with the help of one of these models (Onderwater et al., 1999) .
Two 3D-QSAR models were generated for CYP2B6 substrates (Ekins et al., 1999c) . One is a pharmacophore model built by Catalyst and consisting of three hydrophobes and one hydrogen bond acceptor region. The other partial least-squares model was generated using molecular surface-weighted holistic invariant molecular descriptors. Molecular size, positive electrostatic potential, hydrogen bond acceptors, and hydrophobicity were found to be important for CYP2B6 substrate binding. Although both 3D-QSAR models predicted satisfactory K m values for the majority of the test set molecules, the pharmacophore generated by Catalyst does not overlay the oxidation site of the substrates in the training set. This may be a real limitation for a pharmacophore made for substrates rather than inhibitors.
Only one mammalian P450 (rabbit CYP2C5) has been crystallized to date (Williams et al., 2000) . This is a revolution in the study of the structures of these membrane-bound enzymes, but generation of further structures is impeded by the difficulty in obtaining diffraction quality crystals. In the absence of experimental data, homology modeling becomes an important tool to predict the three-dimensional structures of P450 enzymes. Several reviews have recently addressed the homology modeling of P450s (de Groot and Vermeulen, 1997; Szklarz and Halpert, 1997a; Peterson and Graham, 1998) . Early models were based on one or more of four bacterial crystal structures (Szklarz and Halpert, 1997b) . However, recently models have been built based on CYP2C5 structures, including CYP2B1, 2B4, and 2B5 (Spatzenegger et al., 2001 ) and CYP2C9 (Afzelius et al., 2001) . These homology models provide a structural basis for understanding the mechanism of P450-mediated drug metabolism and drug-drug interactions.
In this study, we used Catalyst to generate pharmacophores for CYP2B6 substrates with the reaction site of each substrate overlaid. In addition, a model of CYP2B6 was constructed by homology modeling based on the crystal structure of CYP2C5. The pharmacophores were combined with the CYP2B6 model by docking the substrates in the active site of CYP2B6. Finally, the pharmacophores were used to predict the K m value for test set molecules in conjunction with the CYP2B6 model. The combined model holds increased potential to study and predict CYP2B6-mediated drug metabolism.
Materials and Methods
Pharmacophore Generation for CYP2B6 Substrates. Pharmacophore generation was done using Catalyst (Molecular Simulations, Inc., San Diego, CA). The structures of CYP2B6 substrates were built interactively using the View Compounds Workbench. The conformational search was performed on each structure using the best conformer generation method in Catalyst. The number of conformers for each substrate was limited to a maximum of 250 with an energy range of 20 kcal/mol. The three-dimensional pharmacophore models were generated based on the K m values and the conformers of the substrates by selecting the default chemical functions in the Feature Dictionary in Catalyst, including hydrogen bond donor or acceptor, hydrophobic, negative or positive ionizable features, etc. The substrates were then fit to the generated pharmacophore models. The results showed that the sites of oxidation of the substrates were not overlaid when they were fit to the pharmacophore models because there is no default function in the Feature Dictionary that can recognize the reaction sites of the substrates and then overlay them together when a pharmacophore is generated.
To force overlay of the reaction sites, a novel function was created to include the structural features of the reaction site for each substrate. The new function was then saved in the Feature Dictionary of Catalyst. For example, for compounds that undergo N-demethylation (Fig. 1) , the common N-CH 3 group for each substrate was put in the novel function in the Feature Dictionary. Catalyst thus can recognize the reaction by searching for the N-CH 3 group in the structure of a pertinent compound. For O-deethylation substrates, the common O-CH 2 CH 3 group was included in the Feature Dictionary. For substrates that undergo C-hydroxylation, the specific substructure, including the reaction site was included in the Feature Dictionary in order for Catalyst to recognize the reaction site. The pharmacophore models were again generated by selecting the hydrogen bond donor, hydrogen bond acceptor, hydrophobic groups, and the novel functions in the Feature Dictionary.
The pharmacophore models generated were evaluated by cost analysis in Catalyst. The lowest cost hypothesis is considered to be the best. However, hypotheses with costs within 10 to 15 arbitrary units of the lowest cost hypothesis should also be considered good candidates (Catalyst Tutorials; Molecular Simulations, Inc.).
Homology Modeling of CYP2B6. The three-dimensional structure of human CYP2B6 was built based on the crystal structure of CYP2C5 (Williams et al., 2000) using Insight II/Homology and Insight II/Discover-3 modules (Molecular Simulations, Inc.). The sequence of CYP2B6 was obtained from SwissProt (accession number P20813). The sequence alignment of CYP2B6 and 2C5 was done by GCG (Wisconsin Package Version 10.0; Genetics Computer Group, Madison, WI). The crystal structure of CYP2C5 lacks the N-terminal residues 1 to 29 and F-G loop residues 212 to 222. Correspondingly, the CYP2B6 was modeled from residues 31 to 491. The segment in CYP2B6 corresponding to residues 212 to 222 in CYP2C5 was constructed based on the coordinates of CYP2C5 containing one of two alternative models for density corresponding to the F-G loop (E. F. Johnson, unpublished observation). For residues 276 to 278, the only segment not considered to be conserved, the coordinates were generated by searching the PDB databank to find the regions of proteins that meet the geometric criteria of the loop. The coordinates of the other residues were assigned based on CYP2C5. The heme group was copied from CYP2C5 into the CYP2B6 model. This preliminary structure was then subjected to molecular mechanics (MM) energy refinement by the Insight II/Discover-3 module with conjugate gradients to a maximum of 1 kcal mol Ϫ1 Å Ϫ1 . The parameters for the heme group were described previously Ornstein, 1991, 1992) . The default cvff force field of Insight II was used for the rest of the model. First, the splices between residues 275 and 276, 278 and 279 were repaired to avoid steric hindrance in these junction regions. The loop of residues 276 to 278 was relaxed using molecular dynamics followed by MM minimization. All the hydrogen atoms were put into minimization while the remaining heavy atoms were fixed. The side chains were minimized with the backbone atoms fixed. A 25-Å sphere and a 3-Å surface layer of water were soaked into and around the CYP2B6 structure to provide a solution environment. Finally, MM energy minimization was performed again on the whole soaked enzyme followed by a 150-ps molecular dynamics calculation with the soaked waters fixed.
The CYP2B6 model was analyzed by Prostat in the Insight II/Homology module. The cutoff used, which represents the significant difference for bond length, bond angle, and torsion from the reference value, is 5 S.D. No bond distances, seven bond angles, and 10 dihedral angles were identified to have more than 5 S.D.
Docking. Benzyloxyresorufin and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) were docked automatically in the active site of the CYP2B6 model using the Insight II/Affinity module. The conformer of each docked substrate that fits the pharmacophore the best was exported from Catalyst to be the initial structure for docking.
Pharmacophore Validation by a Test Set of Substrates. A series of substrates in the test set were used to validate the pharmacophore models. A conformational search was also performed on the test set substrates. Each substrate was mapped to the pharmacophore by the Best Fit Compare method in Catalyst. All conformers of the substrate were checked during the mapping process. Therefore, a number of mappings to the pharmacophore were obtained for each substrate. The predicted activity, which indicates how active the molecule is estimated to be and how well the molecule matches to the pharmacophore, was estimated for each mapping of the substrate. The mapping in which the substrate is located in the orientation for metabolism was selected with the help of the CYP2B6 model. In this manner, the final predicted K m for each substrate was determined.
Results
Pharmacophores of CYP2B6 Substrates. Pharmacophore models were generated for a training set of 16 structurally diverse substrates of CYP2B6 ( Fig. 1) Cluster analysis on the eight hypotheses showed that they can be divided into two groups (Table 2 ). According to the criteria of Catalyst, the lowest cost hypothesis is the best one, although hypotheses within 10 to 15 arbitrary units of the lowest cost should be considered good candidates. Therefore, the lowest cost hypothesis was selected to be the representative pharmacophore in each group. They are hypothesis 1 representing the first group and hypothesis 2 representing the second group (Table 2) .
Catalyst tries to map all functions in a hypothesis to one of the two most active training set molecules. Benzyloxyresorufin and 7-EFC are the two lowest K m substrates in the training set (Table 1) . Their structures differ significantly (Fig. 1) . The molecular size of benzyloxyresorufin is larger than that of 7-EFC. Therefore, Catalyst generated two kinds of pharmacophores primarily based on the different structures of the two lowest K m substrates.
The estimated K m values of benzyloxyresorufin and 7-EFC were predicted by hypotheses 1 and 2, respectively. The experimental K m value (1.3 M) of benzyloxyresorufin is consistent with its estimated K m value by hypothesis 1 (2.0 M) but not by hypothesis 2 (34 M). The experimental K m value (1.7 M) of 7-EFC agrees with the estimated K m value predicted by hypothesis 2 (1.3 M) but not by hypothesis 1 (48 M). These results suggested that the correlation coefficient of hypothesis 1 would be increased if 7-EFC were excluded from the training set substrates. Pharmacophores were regenerated for the remaining 15 substrates in the training set. Two hypotheses were generated (Table 2B) , also including two hydrophobes and one hydrogen bond acceptor. The relative positions of these features are very similar to the two hypotheses in the first group above (Table 2A , hypotheses 1 and 3), but the correlation coefficient for the lowest cost hypothesis is 0.84 rather than 0.76. Similarly, benzyloxyresorufin was excluded from the training substrates to increase the correlation coefficient of hypothesis 2, and pharmacophores were re-generated for the remaining 15 substrates in the training set. Six hypotheses were generated (Table 2B) in which the functions have the same relative positions and are very similar to those of the second group hypotheses (Table 2A ). The correlation coefficient of the lowest cost hypothesis is 0.82 instead of 0.75 before excluding benzyloxyresorufin. The two kinds of pharmacophore models with correlation coefficients 0.84 and 0.82 (Table 2B ) are shown as pharmacophore A and B in Fig. 2 . Both of the pharmacophores include two hydrophobes and one hydrogen bond acceptor located in different relative positions.
Benzyloxyresorufin was mapped to pharmacophore A, and 7-EFC was mapped to pharmacophore B (Fig. 3) . In Fig. 3A , the two phenyl rings of benzyloxyresorufin fit to the hydrophobic features H 1 and H 2 . It can be inferred that the two phenyl rings may form hydrophobic interactions with the enzyme. The oxygen atom on one of the rings of 
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benzyloxyresorufin matches the hydrogen bond acceptor HBA 1 (Fig.  3A) . This oxygen atom may accept a hydrogen atom and form a hydrogen bond with the enzyme or a water molecule in the active site. All functions in the pharmacophore B were fit by 7-EFC (Fig. 3B) . One of the rings fits the hydrophobic function H 3 , and the trifluoromethyl group fits another hydrophobic function H 4 . Both of them may also form hydrophobic interactions with the enzyme. The oxygen atom on the ring fits the hydrogen bond acceptor HBA 2 and may form a hydrogen bond with CYP2B6 or a water molecule in the active site.
Homology Modeling. To determine how well the pharmacophores fit the active site of CYP2B6, a three-dimensional structure of human CYP2B6 was built based on the crystal structure of CYP2C5. The sequence alignment is shown in Fig. 4 . The amino acid residues that have been determined previously to be important for substrate metabolism in the CYP2B subfamily ) are shown in Fig. 5 The mapping results of benzyloxyresorufin with pharmacophore A (Fig. 3A) and 7-EFC with pharmacophore B (Fig. 3B) were compared with the docking results of the two compounds in the active site of CYP2B6 (Figs. 6 and 7, A and B) . Comparison of the positions of benzyloxyresorufin in both Figs. 3A and 6 allowed identification of the reaction site region R, the two hydrophobes H 1 and H 2 , and the hydrogen bond acceptor HBA 1 of pharmacophore A in the active site of the CYP2B6 model (Fig. 6) . No hydrogen bond was identified between benzyloxyresorufin and CYP2B6 from the docking results, suggesting that a water molecule located near the hydrogen bond acceptor may form a hydrogen bond with benzyloxyresorufin. The distances and angles among H 1 , H 2 , and R located in the active site of CYP2B6 are very similar to those of pharmacophore A. Thus, pharmacophore A complements the active site of the CYP2B6 model very well.
Docking of 7-EFC (Fig. 7, A and B) indicated that there are two possible orientations for 7-EFC in the active site of CYP2B6. As with benzyloxyresorufin, no hydrogen bond was found between 7-EFC and CYP2B6. From the location of 7-EFC in the active site and the mapping with pharmacophore B (Fig. 3B) , the reaction site R and the hydrophobes H 3 and H 4 of pharmacophore B can be located in CYP2B6, as shown in Fig. 7A and B. The distances and angles among H 3 , H 4 , and R in pharmacophore B are very similar to those in the active site. This indicates that pharmacophore B also complements the active site of CYP2B6 very well.
The residues within 5Å of the center of the phenyl ring matching H 1 in Fig. 6 are 114 , 115, 206, 298, 363, 367, and 477 . The residues within 5Å of the center of the ring matching H 2 are 206, 297, 298, 301, 302, 363, 477, and 478 . With the exception of residue 301, which has not been tested, all of these residues are consistent with experimental results of site-directed mutagenesis of CYP2B1 in Fig. 5  (Domanski and Halpert, 2001 ).
For the first orientation of 7-EFC (Fig. 7A) , residues 206, 298, 302, 363, 367, 477, and 478 are within 5Å of the center of the phenyl ring matching H 3 , and residues 301, 302, 305, 306, 362, 363, 477, and 479 are within 5Å of the trifluoromethyl group matching H 4 . For the second orientation of 7-EFC (Fig. 7B) , the residues within 5Å of the center of the ring matching H 3 are 114, 206, 297, 298, 302, 367, and The heme group is shown in red. Part of the backbone in the active site is shown as gray ribbons. The substrate recognition site residues determined to be important for substrate metabolism in CYP2B1 are shown in purple.
FIG. 4. Sequence alignment between CYP2B6 and 2C5 from residue 31 to 491.
The GAP method in GCG (Genetics Computer Group) was used for sequence alignment. The sequence identity between CYP2B6 and CYP2C5 is 49%, and the similarity is 61%.
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477. The residues within 5Å of the trifluoromethyl group matching H 4 are 100, 103, 114, 115, 297, and 367 . Most of these residues also show excellent agreement with previous CYP2B1 mutagenesis experiments in Fig. 5 .
Predictions of the Pharmacophores in Conjunction with the CYP2B6 Model. The significance of a pharmacophore is determined by its ability to predict new compounds. Pharmacophores A and B were used to predict the K m values for substrates in the test set (Table  3) in conjunction with the CYP2B6 model. The conformers were calculated for each substrate in the test set. A number of mappings were obtained when each substrate was fit to the pharmacophore by Catalyst because each substrate has a number of conformers. Knowing the orientations and positions of pharmacophores in the active site of CYP2B6 helps to select which mapping is the one most suitable for metabolism by CYP2B6. Table 3 gives the experimental and predicted K m values for the test set molecules. Of the total substrates in the test set, the K m values for most were successfully predicted with at least one of the two pharmacophores. It should be noted that the K m values reported for bupropion and verapamil refer to the racemic mixtures. Since the R-and S-enantiomers may bind differently to the enzyme, K m values were predicted for both forms. For both enantiomers of bupropion, pharmacophores A and B give satisfactory predicted K m values, indicating that bupropion may have more than one binding position in the active site of CYP2B6. For verapamil, the predicted K m values are close to the experimental data except for R-verapamil and pharmacophore B. An exception to the predictive power of the pharmacophores is lidocaine. There are two ethyl groups attached to the N atom (Fig. 1) . Although lidocaine fits pharmacophores A and B very well (the predicted K m is low; Table 3), the two ethyl groups may hinder the access of the N atom to the heme iron. This may explain why the predicted K m is lower than the experimental K m (Table 3) .
Discussion
Two pharmacophores were determined for CYP2B6 substrates in this study, both of which include two hydrophobic regions and one hydrogen bond acceptor. The correlation coefficients of the two pharmacophores are 0.84 and 0.82. Both pharmacophores complement the active site of a CYP2B6 homology model based on CYP2C5 and gave satisfactory estimated K m values for the majority of the test set molecules in conjunction with the protein model. Pharmacophore A is located in one part of the active site, and pharmacophore B is located in another position, with some overlap between the two pharmacophores, indicating that different possible binding locations exist within the active site of the enzyme. The results are consistent with previous QSAR studies on CYP2B proteins that suggested the importance of hydrophobic and electronic properties in the binding of substrates (Lewis et al., 1999; Ekins et al., 1999c) .
Initially, we sought to investigate the active-site features of CYP2B6 by combining our new three-dimensional homology model with the existing substrate pharmacophore of CYP2B6 generated by Catalyst (Ekins et al., 1999c) . Following the procedures in that study we recreated the pharmacophore, which gave satisfactory predicted K m values for the majority of the test set molecules (data not shown). However, we realized that the oxidation sites of the substrates in the training set had not been overlaid when they were mapped to the pharmacophore. Since the site of oxidation of the substrates should point toward the heme iron in the enzyme, a new function was made and saved in the Feature Dictionary in Catalyst to force the reaction site of each substrate to be overlaid when the pharmacophores were generated.
In constructing the new pharmacophores, we made some modifications to the initial training set of 16 compounds. In particular, antipyrine was deleted due to questions about the validity of the very high K m value (17.7 mM). In addition, benzphetamine and cinnarizine were moved to the test set (Table 1) . These three compounds were replaced in the training set by arteether, amitriptyline, and propofol. Five compounds with different metabolic pathways are thus included in the test set (Table 3) in this study to assess pharmacophore A and B. In addition, the R-and S-enantiomers of bupropion and verapamil in the test set were considered. The reported K m values of the two compounds correspond to the racemic mixtures. However, the R-and S-forms differ in their binding with the CYP2B6 model. Therefore, the K m values were predicted for both R-and S-enantiomers of the two compounds. Consideration of the stereochemistry had relatively little impact with bupropion or with pharmacophore A and verapamil. However, pharmacophore B predicted a K m in the millimolar range The heme group is shown in red. Benzyloxyresorufin is shown in orange, and residues within 5 Å are shown in green. The reaction site R and hydrophobes H 1 and H 2 of pharmacophore A are located according to the orientation and position of benzyloxyresorufin in the active site when compared with the mapping in Fig. 3A . The distance between H 1 (the center of the phenyl ring matching H 1 ) and R is 3.9 Å, and the angle ЄH 1 RH 2 equals 90.3°. The values are very similar to the corresponding distance (4.0 Å) and angle (88.6°) in pharmacophore A (Fig. 2A) . The distance between R and H 2 does not vary.
for R-verapamil. In the article by Ekins et al. (1999c) , the R-and S-forms were not distinguished when the K m values were predicted for bupropion and verapamil.
The pharmacophore model made by Ekins consists of three hydrophobes and one hydrogen bond acceptor region. The pharmacophores generated in this study include two instead of three hydrophobes, one hydrogen bond acceptor, and an additional reaction site. If the mapping of 7-EFC with the pharmacophore in the article by Ekins et al. (1999c) is compared with that (Fig. 3B ) in this study, we can see that the phenyl ring to which the ethoxy group attaches matches a hydrophobe in both studies. The trifluoromethyl group attached to position 4 of the other ring also fits a second hydrophobe in both studies. Therefore, the hydrophobicity of the trifluoromethyl group and the phenyl ring may be very important for 7-EFC binding. If the structures of 7-ethoxy-4-trifluoromethylcoumarin, 4-chloromethyl-7-ethoxycoumarin, and 7-ethoxycoumarin ( Fig. 1) 
